ViCentra Believes Smaller Is Better For Insulin Pumps

Medtech Insight spoke to the manufacturers of the smallest commercially available insulin pump to learn more about how it works, the market factors impacting it, and how scaling up a business can throw up unexpected challenges.

ViCentra's Kaleido pump and handset • Source: ViCentra

Over the past decade, technological advances have miniaturized technologies that make living with diabetes easier, safer and overall, much less unpleasant.

Insulin pumps, glucose monitors, and systems that allow for the connection of these two types of devices have become increasingly...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Diabetic Care

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.